Skip to content

Nitric Oxide Biomarkers in Glaucoma and Tinnitus

Nitric Oxide Biomarkers in Glaucoma and Tinnitus - NO biomarkers

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON49687
Enrollment
40
Registered
2020-04-15
Start date
2020-08-03
Completion date
Unknown
Last updated
2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glaucoma

Interventions

None listed

Sponsors

Universitair Medisch Centrum Groningen
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 50-70 years of age For patients only: Diagnosed primary open angle glaucoma For those with tinnitus, response of tinnitus *always* or *sometimes* in F1 questionnaire Written informed consent.

Exclusion criteria

Exclusion criteria: Patients taking ototoxic medications will be excluded from this study. These include: loop diuretics, Apirin, NSAIDs, and chemotherapy agents. For healthy controls only, glaucoma or family history of glaucoma. This will be determined by the ophthalmologic screening described in section 3.

Design outcomes

Primary

MeasureTime frame
Concentrations of amino acids which mark nitric oxide production in glaucoma patients both with and without tinnitus.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)